NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

I know I am late submitting this, but after reading these seems like we are missing or light on questions concerning Dr. Duffy's sudden departure from NWBO leaving to go back to work for Merck.

I Suggest this question:
The company recruited Kevin Duffy, Ph.D. on the strength of his experience working in cancer immunotherapy and his experience dealing with the regulatory agencies. Was his departure unexpected or was it more that he has successfully completed the work NWBO wanted him to complete and returned to Merck as had been planned from the start? Why shouldn't shareholders view silence about the reasons for his sudden departure as a sign that after getting a closer look from within NWBO at what was going on with DCVAX-L that he concluded the trial is destined to fail, panicked about his poor choice of career moves and begged Merck to give him his old position back?